The fact that biologic agents interact with a specific cytokine, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-17 or -23) in a targeted manner has revolutionized the capacity to treat psoriasis compared to the era of a more generalized immunosuppression reflected by the traditional oral medications. Here, IL17A is linked to psoriasis.